American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

ProPhase Labs, Inc. (PRPH)

$0.01 -3.16% OTC: PRPH · 15-min delayed

NEW YORK, New York
Public · OTC: PRPH

Visit website Follow

$4.3MRevenue · FY2025

-$14.7MNet income

PRPHOTC

About ProPhase Labs, Inc.

PROPHASE LABS INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: PRPH
Headquarters: NEW YORK, New York
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: PRPH OTC
SEC CIK: 868278
EIN: 232577138
SIC: 2834 Pharmaceutical Preparations

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show ProPhase Labs, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/prophase-labs-inc/"><img src="https://americancompanies.com/badge/prophase-labs-inc.svg" alt="ProPhase Labs, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow ProPhase Labs, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $4.3M
Net income: -$14.7M
Total assets: $59.9M

Source: SEC EDGAR · updated Jun 8, 2026

OTC: PRPH

$0.01 -3.16%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.01 $6.08

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

ProPhase Labs, Inc. (PRPH) Stock Price

Reported a net loss of $14.7M in FY2025.
Trading 100% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review ProPhase Labs, Inc..

Write a review

Newsroom

News about ProPhase Labs, Inc.

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value GlobeNewswire Inc. · 2026-01-05 · neutral ProPhase Labs Posts Narrower Q2 Loss The Motley Fool · 2025-08-13 · neutral ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform GlobeNewswire Inc. · 2025-06-06 · positive ProPhase Labs Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc. · 2024-11-08 · positive Antibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS Insider GlobeNewswire Inc. · 2024-08-07 · positive Rare Stock Picks In May 2024 - From 29 Discerning Analysts Seeking Alpha · 2024-06-06

News & sentiment via Polygon.io

FAQ

ProPhase Labs, Inc.: frequently asked questions

Is ProPhase Labs, Inc. an American company?

ProPhase Labs, Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is ProPhase Labs, Inc. headquartered?

ProPhase Labs, Inc. is headquartered in New York, New York, United States.

Is ProPhase Labs, Inc. publicly traded?

Yes — ProPhase Labs, Inc. is a publicly traded company. Its stock trades under the ticker symbol PRPH on the OTC.

What does ProPhase Labs, Inc. do?

ProPhase Labs, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore